
Omnicell, Inc. (NASDAQ:OMCL – Free Report) – Research analysts at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for Omnicell in a report released on Tuesday, November 17th. Zacks Research analyst Team now forecasts that the company will earn $1.73 per share for the year, up from their previous estimate of $1.49. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.64 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.24 EPS, Q2 2027 earnings at $0.24 EPS, Q3 2027 earnings at $0.29 EPS, Q4 2027 earnings at $0.40 EPS, FY2027 earnings at $1.17 EPS, Q1 2028 earnings at $0.31 EPS, Q2 2028 earnings at $0.32 EPS, Q3 2028 earnings at $0.33 EPS and FY2028 earnings at $1.33 EPS.
OMCL has been the topic of a number of other reports. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. BTIG Research reissued a “neutral” rating on shares of Omnicell in a report on Friday, November 13th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Weiss Ratings downgraded shares of Omnicell from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, November 9th. Finally, Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.86.
Omnicell Stock Performance
Shares of OMCL stock opened at $34.66 on Thursday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 36.10, a PEG ratio of 0.85 and a beta of 0.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. The company has a 50-day simple moving average of $35.11 and a 200 day simple moving average of $38.20. Omnicell has a 52 week low of $31.75 and a 52 week high of $55.00.
Omnicell (NASDAQ:OMCL – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The company had revenue of $307.85 million for the quarter, compared to analysts’ expectations of $304.44 million. During the same period in the prior year, the firm earned $0.51 EPS. Omnicell’s quarterly revenue was down .9% compared to the same quarter last year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new stake in shares of Omnicell in the second quarter worth $26,000. Fulcrum Asset Management LLP increased its holdings in Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock valued at $40,000 after purchasing an additional 1,116 shares during the period. Versant Capital Management Inc raised its position in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Omnicell by 21.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock worth $89,000 after purchasing an additional 469 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Omnicell during the 2nd quarter worth $105,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.
More Omnicell News
These are some of the OMCL news items that stood out recently:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $1.73 from $1.49, above the $1.64 consensus, and lifted its Q4 2026 forecast to $0.23 from $0.07. It also made a modest increase to its Q2 2027 estimate, to $0.24 from $0.23. Omnicell analyst-estimate report
- Negative Sentiment: The analyst cut its FY2027 EPS forecast to $1.17 from $1.27 and FY2028 to $1.33 from $1.73. It also lowered estimates for several 2027–2028 quarters, including Q4 2027 to $0.40 from $0.47 and Q3 2028 to $0.33 from $0.46. These broader out-year reductions signal a weaker earnings outlook and may offset the near-term upgrades. Omnicell analyst-estimate report
Omnicell Company Profile
Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.
Read More
- Five stocks we like better than Omnicell
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
